Table 1 Completed clinical trials using MSCs transplantation to treat liver cirrhosis, registered under ClinicalTrials.gov
From: Mesenchymal stromal cells: promising treatment for liver cirrhosis
NCT number | Dates | Conditions | Study phase | Interventions | Cell source | No. of patients | Primary outcome measures | Locations |
|---|---|---|---|---|---|---|---|---|
NCT01342250 | 2010.10–2011.10 | Liver Cirrhosis | Phase 1 Phase 2 | Conventional therapy plus hUC-MSCs treatment | hUC-MSCs | 20 | Overall Survival | China |
NCT01591200 | 2021.06–2016.04 | Alcoholic Liver Cirrhosis | Phase 2 | Allogeneic MSCs injected through the hepatic artery | BM-MSCs | 40 | Safety | India |
NCT01875081 | 2012.11–2016.03 | Alcoholic Liver Cirrhosis | Phase 2 | 5*107 autologous BM-MSCs injected through the hepatic artery | BM-MSCs | 72 | Histopathological evaluation | Korea |
NCT01220492 | 2009.05–2016.04 | Liver Cirrhosis | Phase 1 Phase 2 | Taken i.v. once per 4 weeks, at a dose of 0.5*106 MSC/kg body for 8 weeks | UC-MSCs | 266 | 1.Survival time; 2. Incidence of HCC events | China |
NCT00420134 | 2006.02–2009.06 | Liver Failure Cirrhosis | Phase 1 Phase 2 | Progenitor of hepatocyte derived from Mesenchymal stem cell injected into portal vein | From the end-stage liver disease | 30 | 1.Liver function test; 2. MELD score | Iran |
NCT04243681 | 2019.07–2020.09 | Liver Cirrhosis | Phase 4 | MSCs and Hematopoietic Stem cell injected through hepatic artery | CD34 + cell and MSCs | 5 | Safety | India |
NCT01454336 | 2010.06–2013.07 | Liver Fibrosis | Phase 1 | Autologous MSCs injected via portal vein; 30 mg pioglitazone daily for 24 months | BM-MSCs | 3 | 1. ALT, AST, Serum Albumin levels; 2. The decrease in grade of liver fibrosis | Iran |
NCT01062750 | 2012.10–2015.05 | Liver Cirrhosis | Not Applicable | Autologous AT-MSCs via intrahepatic arterial catheterization | AT-MSCs | 4 | All cause harmful events | Japan |